date:Nov 06, 2013
rolactam business has hit results this year, and DSM said it was still looking at options ranging from partnerships to divestment, as well as searching for a partner with which to expand its pharmaceuticals business in Asia.
DSM shares rose more than 2 percent in early trading to stand at 57.00 euros.
DSM shifted strategy in 2010 and has spent more than 2.2 billion euros on acquisitions as it moved away from lower-margin bulk chemicals to focus on less cyclical businesses including food ingred